Corrigendum to “Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan” [Lung Cancer, 129 (March) (2019) 55–62]

Lung Cancer ◽

10.1016/j.lungcan.2019.04.010 ◽

2019 ◽

Vol 132 ◽

pp. 157-158

Author(s):

Satoshi Watanabe ◽

Hiroshige Yoshioka ◽

Hiroshi Sakai ◽

Katsuyuki Hotta ◽

Mitsuhiro Takenoyama ◽

...

Keyword(s):

Lung Cancer ◽

Stage Iv ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Phase 1B ◽

Gemcitabine And Cisplatin

Download Full-text

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan

Lung Cancer ◽

10.1016/j.lungcan.2019.01.005 ◽

2019 ◽

Vol 129 ◽

pp. 55-62 ◽

Cited By ~ 6

Author(s):

Satoshi Watanabe ◽

Hiroshige Yoshioka ◽

Hiroshi Sakai ◽

Katsuyuki Hotta ◽

Mitsuhiro Takenoyama ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Phase 1B ◽

Gemcitabine And Cisplatin

Download Full-text

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70461-9 ◽

2014 ◽

Vol 15 (13) ◽

pp. 1433-1441 ◽

Cited By ~ 72

Author(s):

Pasi A Jänne ◽

Sai-Hong I Ou ◽

Dong-Wan Kim ◽

Geoffrey R Oxnard ◽

Renato Martins ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

A randomized, double-blind, multicenter phase 2 trial of denosumab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps8130 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS8130-TPS8130

Author(s):

David R. Spigel ◽

Fred R. Hirsch ◽

Richard H. De Boer ◽

Ronald B. Natale ◽

Jeffrey Crawford ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

Phase 2 Trial ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

Acceptability and feasibility of S-1 plus cisplatin adjuvant chemotherapy for completely resected non-small cell lung cancer: an open-label, single arm, multicenter, phase 2 trial

Journal of Thoracic Disease ◽

10.21037/jtd-20-3293 ◽

2021 ◽

Vol 13 (4) ◽

pp. 2224-2232

Author(s):

Shugo Uematsu ◽

Atsushi Sano ◽

Kazutoshi Isobe ◽

Kazuhiro Usui ◽

Jun Matsumoto ◽

...

Keyword(s):

Lung Cancer ◽

Adjuvant Chemotherapy ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Phase 2 Trial ◽

Multicenter Phase

Download Full-text

First Line Treatment with Erlotinib Plus Bevacizumab or with Erlotinib Alone in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (NEJ026): An Open-Label, Randomized, Multicenter, Phase 3 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271416 ◽

2018 ◽

Author(s):

Haruhiro Saito ◽

Tatsuro Fukuhara ◽

Naoki Furuya ◽

Kana Watanabe ◽

Shunichi Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

Durvalumab, Tremelimumab Alone or in Combination With Low-Dose or Hypofractionated Targeted Radiotherapy in Metastatic Non-Small Cell Lung Cancer Refractory to Prior PD-1 Therapy: A Multicentre, Open-Label, Randomized, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3922682 ◽

2021 ◽

Author(s):

Jonathan D. Schoenfeld ◽

Anita Giobbie-Hurder ◽

Srinika Ranasinghe ◽

Katrina Z. Kao ◽

Ana Lako ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Low Dose ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Targeted Radiotherapy ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)70046-x ◽

2015 ◽

Vol 16 (3) ◽

pp. 328-337 ◽

Cited By ~ 75

Author(s):

Luis Paz-Ares ◽

Jörg Mezger ◽

Tudor E Ciuleanu ◽

Jürgen R Fischer ◽

Joachim von Pawel ◽

...

Keyword(s):

Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Therapy ◽

Line Therapy ◽

Randomised Controlled

Download Full-text

Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial

Annals of Oncology ◽

10.1016/j.annonc.2020.10.479 ◽

2021 ◽

Vol 32 (1) ◽

pp. 85-96 ◽

Cited By ~ 1

Author(s):

M. Shi ◽

A. Gu ◽

H. Tu ◽

C. Huang ◽

H. Wang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2020.11.026 ◽

2020 ◽

Author(s):

Ligang Xing ◽

Gang Wu ◽

Luhua Wang ◽

Jiancheng Li ◽

Jianhua Wang ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Phase 2 Trial ◽

Unresectable Stage ◽

Open Label Phase ◽

Epidermal Growth

Download Full-text

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30140-6 ◽

2020 ◽

Vol 21 (6) ◽

pp. 786-795 ◽

Cited By ~ 18

Author(s):

Catherine A Shu ◽

Justin F Gainor ◽

Mark M Awad ◽

Codruta Chiuzan ◽

Claud M Grigg ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Phase 2 Trial

Download Full-text